PhRMA Chief Steve Ubl to Step Down After a Decade Leading Big Pharma's Top Lobby

Steve Ubl, the president and chief executive of the Pharmaceutical Research and Manufacturers of America, is set to depart the powerful drug industry lobbying group by the end of the year, capping a ten-year run at the helm of one of Washington's most influential trade associations.

The announcement was disclosed during a board call, signaling a planned transition rather than an abrupt exit. Ubl has led PhRMA since 2015, steering the organization through some of the most turbulent periods in pharmaceutical policy, including battles over drug pricing legislation and the political firestorm surrounding the Inflation Reduction Act.

Under Ubl's leadership, PhRMA spent hundreds of millions of dollars on lobbying efforts and public advocacy campaigns aimed at shaping drug pricing policy and defending brand-name manufacturers against mounting pressure from Congress and successive administrations. The group consistently ranked among the top spenders in Washington's lobbying landscape.

His tenure was marked by both victories and setbacks. While PhRMA successfully fended off several sweeping pricing proposals, the passage of the Inflation Reduction Act in 2022 — which granted Medicare the authority to negotiate drug prices — represented a significant blow to the industry's long-standing policy positions.

The search for Ubl's successor is expected to begin in earnest as the year draws to a close. Whoever takes the reins will inherit a complex landscape, with drug pricing remaining a flashpoint in both Congress and the executive branch, and the first round of Medicare drug negotiations already underway.

PhRMA did not immediately provide additional comment on the leadership transition or a timeline for naming a new chief executive.